The prescription drug Synagis
® (
palivizumab) is manufactured by MedImmune, LLC. It is given to children who have a high risk for developing serious complications from respiratory syncytial virus (
RSV) infections. Although it cannot prevent a child from becoming infected with RSV, it can help minimize the potentially serious complications that this infection can cause.
Synagis is given as an intramuscular (IM) injection (an injection into a muscle) once a month during the RSV season, which is usually from November to April. The injection is usually administered in the thigh muscle.
(Click Synagis for more information on this MedImmune medication, including how it works to prevent serious RSV infections. This resource also describes possible side effects, dosing instructions, and safety precautions to be aware of with this drug.)
HealthSavvy Sign In
|